Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis

NCT01986920 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Seborrheic Keratosis (SK)

Interventions

DRUG: A-101 25%
DRUG: A-101 32.5%
DRUG: A-101 40%
DRUG: A-101 Vehicle

Sponsor

Aclaris Therapeutics, Inc.